Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication

P.S. Joshi, N. Sanakkayala, L. Kirkpatrick, P.S. Terse

Open source

DOI
10.1016/j.yrtph.2019.104433
Published
2019-11
Container
Regulatory Toxicology and Pharmacology
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.yrtph.2019.104433,
  title = {Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication},
  author = {P.S. Joshi and N. Sanakkayala and L. Kirkpatrick and P.S. Terse},
  year = {2019},
  journal = {Regulatory Toxicology and Pharmacology},
  doi = {10.1016/j.yrtph.2019.104433},
  url = {https://doi.org/10.1016/j.yrtph.2019.104433}
}

RIS

TY  - JOUR
TI  - Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication
AU  - P.S. Joshi
AU  - N. Sanakkayala
AU  - L. Kirkpatrick
AU  - P.S. Terse
PY  - 2019
JO  - Regulatory Toxicology and Pharmacology
DO  - 10.1016/j.yrtph.2019.104433
UR  - https://doi.org/10.1016/j.yrtph.2019.104433
ER  - 

APA

Joshi, P., Sanakkayala, N., Kirkpatrick, L., & Terse, P. (2019). Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication. Regulatory Toxicology and Pharmacology. https://doi.org/10.1016/j.yrtph.2019.104433

Source records